Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2011

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

ixabepilone

This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.

DRUG

lapatinib ditosylate

Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.

Trial Locations (4)

95817

University of California Davis Cancer Center, Sacramento

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

71130-3932

Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, Davis

OTHER